Kymera Therapeutics
OverviewSuggest Edit
Kymera Therapeutics is a biotechnology company aimed to create medicines for patients with previously untreatable diseases. The company specializes in the field of targeted protein degradation (TPD) accessing the body’s innate protein recycling machinery to degrade rather than inhibit dysregulated, disease-causing proteins. Its proprietary integrated degradation platform, Pegasus, consists of informatics-driven target identification, novel E3 ligases, proprietary ternary complex predictive modeling capabilities and degradation tools.
| Type | Private | |
| Founded | 2017 | |
| HQ | Cambridge, MA, US | Map |
| Website | kymeratx.com |
Recent NewsAll News
- Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
- Kymera Therapeutics Announces Key Leadership Appointments
- Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
- Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
Latest Updates
| Employees (est.) (Jan 2021) | 73 | (+8%) |
| Cybersecurity rating | A | More |
Key People/Management at Kymera Therapeutics
Nello Mainolfi
Founder, President, Chief Executive Officer & Director
Jared Gollob
Chief Medical Officer
Bruce Jacobs
Chief Financial Officer
Richard Chesworth
Chief Scientific Officer
Karen Martin
Vice President, Head of Intellectual Property
Brian Albarran
Vice President, Strategy and Operations
Kymera Therapeutics Office Locations
Kymera Therapeutics has an office in Cambridge
Cambridge, MA, US (HQ)
300 Tech Square, 300 Technology Square 2nd Floor
Kymera Therapeutics Financials and Metrics
Summary Metrics
Founding Date | 2017 |
Kymera Therapeutics total Funding | $197 m |
Kymera Therapeutics latest funding size | $102 m |
Time since last funding | a year ago |
Kymera Therapeutics investors | BlackRock, Atlas Venture, Bessemer Venture Partners, Wellington Management, Redmile Group, Lilly Ventures, Pfizer Venture Investments, Amgen Ventures, Aju IB Investment, Hatteras Venture Partners, Rock Springs Capital, Biotechnology Value Fund, Sanofi-Genzyme BioVentures, Bain Capital Life Sciences, 6 Dimensions Capital, Janus Henderson Investors, MRL Ventures Fund |
Kymera Therapeutics's latest funding round in March 2020 was reported to be $102 m. In total, Kymera Therapeutics has raised $197 m
Kymera Therapeutics Cybersecurity Score
Kymera Therapeutics Online and Social Media Presence
1.78k Twitter followers
Kymera Therapeutics has 1.78k Twitter Followers. The number of followers has increased 3.2% month over month and increased 6.3% quarter over quarter
Kymera Therapeutics's Trends
Twitter Engagement Stats for @KymeraTx
392
Tweets
120
Following
1.8k
Followers
7
Tweets last 30 days
11.7
Avg. likes per Tweet
100%
Tweets with engagement
Kymera Therapeutics News and Updates
January 05, 2021
Kymera Therapeutics to Present at the 39th Annual J.P. Morgan Healthcare Conference on Thursday, January 14, 2021
WATERTOWN, Mass., Jan. 05, 2021 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel small molecule protein degrader medicines, today announced that the Company will present at the virtual 39th Annual J.P.…
December 16, 2020
Kymera Therapeutics Announces Key Leadership Appointments
WATERTOWN, Mass., Dec. 16, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the appointments of William Leong, PhD, as Vice President…
December 07, 2020
Kymera Therapeutics Presents Preclinical Data on IRAKIMiD and STAT3 Programs at Virtual 62nd American Society of Hematology (ASH) Annual Meeting
WATERTOWN, Mass., Dec. 07, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation to deliver novel, small molecule protein degrader therapeutics, today announced the company presented preclinical data that further suppo…
November 23, 2020
Kymera Therapeutics to Present at the Piper Sandler 32nd Annual Healthcare Conference
WATERTOWN, Mass., Nov. 23, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradati…
November 11, 2020
Kymera Therapeutics to Present at the Stifel 2020 Virtual Healthcare Conference
WATERTOWN, Mass., Nov. 11, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company focused on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradati…
October 12, 2020
Kymera Therapeutics to Deliver Two Podium Presentations at 3rd Annual Targeted Protein Degradation Summit
WATERTOWN, Mass., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader therapeutics, will share two key presentations at the 3rd Annual Targeted Protein …
Kymera Therapeutics Blogs
December 07, 2020
62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020
Poster Presentation: Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations
The post 62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition, December 5-8, 2020 appeared first on Kymera Therape…
December 01, 2020
Becoming CEO: The First 18 Months
I’ve held many titles and even more roles at Kymera since founding the company with Bruce Booth and Atlas Venture four years ago. But it’s been just over 12 months since we announced my appointment to CEO, and nearly 18 months in the role. Looking back now, I could not imagine a more challenging and…
November 04, 2020
IRAK4 Degrader to Take on Innate Immunity, November 3, 2020
Mullard, A. IRAK4 degrader to take on innate immunity. Nat Biotechnol 38, 1221–1223 (2020). https://doi.org/10.1038/s41587-020-0724-8
The post IRAK4 Degrader to Take on Innate Immunity, November 3, 2020 appeared first on Kymera Therapeutics.
October 15, 2020
3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi, October 13-15, 2020
Oral Presentation: Targeted Protein Degradation Beyond Oncology
The post 3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi, October 13-15, 2020 appeared first on Kymera Therapeutics.
October 14, 2020
3rd Annual Targeted Protein Degradation (TPD) Summit, October 13-15, 2020
Oral Presentation: PK/PD Relationship in Targeted Protein Degradation
The post 3rd Annual Targeted Protein Degradation (TPD) Summit, October 13-15, 2020 appeared first on Kymera Therapeutics.
October 09, 2020
5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 9-11, 2020
Poster Presentation: Interim results from non-interventional study to evaluate cutaneous and circulating biomarkers for a novel IRAK4-targeted therapeutic in patients with hidradenitis suppurativa
The post 5th Annual Symposium on Hidradenitis Suppurativa Advances (SHSA), October 9-11, 2020 appeared …
Kymera Therapeutics Frequently Asked Questions
When was Kymera Therapeutics founded?
Kymera Therapeutics was founded in 2017.
Who are Kymera Therapeutics key executives?
Kymera Therapeutics's key executives are Nello Mainolfi, Jared Gollob and Bruce Jacobs.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics has 73 employees.
Who are Kymera Therapeutics competitors?
Competitors of Kymera Therapeutics include Foghorn Therapeutics, Urovant Sciences and Rubius Therapeutics.
Where is Kymera Therapeutics headquarters?
Kymera Therapeutics headquarters is located at 300 Tech Square, 300 Technology Square 2nd Floor, Cambridge.
Where are Kymera Therapeutics offices?
Kymera Therapeutics has an office in Cambridge.
How many offices does Kymera Therapeutics have?
Kymera Therapeutics has 1 office.
Learn about Craft real-time company insights
Receive alerts for 300+ data fields across thousands of companies